Research programme: anti-interleukin-13 monoclonal antibody fragment - UCB Pharma

Drug Profile

Research programme: anti-interleukin-13 monoclonal antibody fragment - UCB Pharma

Alternative Names: Anti-IL-13 Fab'

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator UCB Pharma SA
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in Belgium (Inhalation, Aerosol)
  • 28 Sep 2011 Preclinical trials in Asthma in Belgium (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top